علاج الالتهاب الرئوي اليوزيني المزمن مع ارتفاع IgE

References

DOI: 10.2147/TCRM.S157882

• Omalizumab, a monoclonal antibody against IgE, was used in a patient with CEP after the second relapse in 2 years.
• This patient had an elevated IgE and responded to the omalizumab injections.
• They were able to taper the dose of omalizumab by 50% every 6 months.
• Eighteen months after initial presentation, mepolizumab was started at a dose of 100 mg every 4 weeks.
• Therefore, reslizumab at a dose of 3 mg/kg was initiated every 4 weeks.
• Mepolizumab and reslizumab prevent binding of circulating IL-5 to eosinophils.
• After starting this therapy, her peripheral blood eosinophilia decreased, and her symptoms disappeared while tapering her glucocorticoids.